State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, 200438, PR China.
Department of Infectious Diseases, Chongqing Three Gorges Central Hospital, Chongqing, 404000, PR China.
Antiviral Res. 2021 Nov;195:105178. doi: 10.1016/j.antiviral.2021.105178. Epub 2021 Sep 10.
Telbivudine (LdT) - a synthetic thymidine β-L-nucleoside analogue (NA) - is an effective inhibitor for hepatitis B virus (HBV) replication. The quasispecies spectra in the reverse transcriptase (RT) region of the HBV genome and their dynamic changes associated with LdT treatment remains largely unknown.
We prospectively recruited a total of 21 treatment-naive patients with chronic HBV infection and collected sequential serum samples at five time points (baseline, weeks 1, 3, 12, and 24 after LdT treatment). The HBV RT region was amplified and shotgun-sequenced by the Ion Torrent Personal Genome Machine (PGM)® system. We reconstructed full-length haplotypes of the RT region using an integrated bioinformatics framework, including de novo contig assembly and full-length haplotype reconstruction. In addition, we investigated the quasispecies' dynamic changes and evolution history and characterized potential NAs resistant mutations over the treatment course.
Viral quasispecies differed obviously between patients with complete (n = 8) and incomplete/no response (n = 13) at 12 weeks after LdT treatment. A reduced d/d ratio in quasispecies demonstrated a selective constraint resulting from antiviral therapy. The temporal clustering of sequential quasispecies showed different patterns along with a 24-week observation, although its statistic did not differ significantly. Several patients harboring pre-existing resistant mutations showed different clinical responses, while NAs resistant mutations were rare within a short-term treatment.
A complete profile of quasispecies reconstructed from in-depth shotgun sequencing may has important implications for enhancing clinical decision in adjusting antiviral therapy timely.
替比夫定(LdT)是一种合成胸腺嘧啶β-L-核苷类似物(NA),是一种有效的乙型肝炎病毒(HBV)复制抑制剂。HBV 基因组逆转录酶(RT)区的准种谱及其与 LdT 治疗相关的动态变化在很大程度上尚不清楚。
我们前瞻性地招募了 21 名初治慢性 HBV 感染患者,在 LdT 治疗后 5 个时间点(基线、第 1、3、12 和 24 周)采集连续血清样本。使用 Ion Torrent Personal Genome Machine(PGM)®系统对 HBV RT 区进行扩增和鸟枪法测序。我们使用集成的生物信息学框架(包括从头组装和全长单倍型重建)来重建 RT 区的全长单倍型。此外,我们研究了治疗过程中准种的动态变化和进化历史,并描述了潜在的 NAs 耐药突变。
在 LdT 治疗 12 周后,完全(n=8)和不完全/无应答(n=13)患者的病毒准种明显不同。准种的 d/d 比值降低表明抗病毒治疗产生了选择压力。尽管其统计学差异不显著,但随着 24 周的观察,连续准种的时间聚类显示出不同的模式。一些预先存在耐药突变的患者表现出不同的临床反应,而在短期治疗中,NAs 耐药突变很少见。
从深度鸟枪法测序重建的准种完整图谱可能对及时调整抗病毒治疗的临床决策具有重要意义。